TOKYO, Dec 2, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at ...
OTTAWA, Ontario — Looking for Alzheimer’s disease (AD) biomarkers in plasma instead of cerebrospinal fluid (CSF) is a simpler form of screening individuals for AD pathology and could result in earlier ...
Global prevalence estimates show Alzheimer’s disease accounts for most dementia, with ~57 million people affected in 2021 and numbers projected to triple by 2050. People and health systems face rising ...
TORONTO — An expert panel convened by the Alzheimer’s Association has released the first clinical guidelines to help clinicians choose the most appropriate blood-based biomarker (BBM) test to aid in ...
Brain-derived extracellular vesicle (EV) biomarkers represent a promising frontier for liquid biopsy development targeting the nervous system. They offer strong potential for enabling minimally ...
Over the past decade, fluid biomarkers have transformed the conceptual and clinical framework of neurodegenerative diseases. In Alzheimer’s disease (AD), ...
pTau217, also called phosphorylated tau at threonine 217, is a specific blood-based biomarker for brain amyloid β pathology. When validated against CSF Aβ42/40 and PET imaging, the biomarker showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results